Dual Agonists in Obesity

The emergence of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists marks a significant advancement in pharmacological obesity treatment. These agents simultaneously activate two incretin receptors, achieving weight loss magnitudes that approach those observed with bariatric surgery.

Mechanism of Dual Receptor Activation

GIP receptors are expressed on adipocytes, pancreatic beta cells, and neurons in the hypothalamus and brainstem. GLP-1 receptors are distributed across pancreatic islets, gastrointestinal epithelium, and central appetite-regulation circuits. Co-activation of both receptors produces synergistic effects on satiety signaling, gastric emptying modulation, and energy expenditure. Preclinical studies demonstrate that dual agonism suppresses food intake more effectively than selective GLP-1 agonism alone.

Retatrutide

Retatrutide (LY3437943) is a unimolecular GIP/GLP-1/glucagon triple agonist that has demonstrated remarkable efficacy in phase 2 trials. Participants receiving the highest dose achieved mean weight reductions of 24.2% over 48 weeks. The inclusion of glucagon receptor activity appears to enhance hepatic lipid metabolism and resting energy expenditure, contributing to superior weight loss compared to selective or dual agonists.

Survodutide

Survodutide (BI 456906) is a GIP/GLP-1 dual agonist in phase 3 development. In a phase 2 trial involving adults with obesity and type 2 diabetes, survodutide produced weight reductions of 18.7% at the highest dose over 46 weeks. Notably, survodutide also demonstrated significant improvements in hepatic steatosis, positioning it as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH).

Safety Profile

Common adverse events across dual agonists include nausea, vomiting, and diarrhea, which are generally mild to moderate and diminish over time. Concerns regarding pancreatitis, gallbladder disease, and thyroid C-cell tumors require ongoing monitoring through post-marketing surveillance.

Future Directions

Triple agonists combining GIP, GLP-1, and glucagon receptor activities may further improve metabolic outcomes. Oral formulations and less frequent dosing schedules are in development to improve patient adherence and expand access to these transformative therapies.